The effect of testosterone on ovulatory function in transmasculine individuals
An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have di...
Uložené v:
| Vydané v: | American journal of obstetrics and gynecology Ročník 223; číslo 2; s. 229.e1 - 229.e8 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.08.2020
|
| Predmet: | |
| ISSN: | 0002-9378, 1097-6868, 1097-6868 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have directly examined ovulatory function in transmasculine individuals using injectable testosterone.
Our primary objective was to determine the effect of testosterone on ovulatory suppression in transmasculine individuals. Secondary objectives were to determine predictors of ovulation in transmasculine individuals on testosterone, and to assess the effect of testosterone on antimüllerian hormone.
This prospective observational study recruited participants from a community clinic that provides gender-affirming hormone therapy. Enrolled individuals were assigned female at birth and were currently using or seeking to initiate masculinizing therapy with injectable testosterone esters (transmasculine individuals). Over a 12-week study period, participants collected daily urine samples for pregnanediol-3-glucoronide testing and completed daily electronic bleeding diaries. We assessed monthly serum mid-dosing interval testosterone, estradiol and sex hormone binding globulin, and antimüllerian hormone values at baseline and study end. Ovulation was defined as pregnanediol-3-glucoronide greater than 5 μg/mL for 3 consecutive days. The primary outcome was the proportion of participants who ovulated during the study period. We examined predictors of ovulation such as age, length of time on testosterone, serum testosterone levels, body mass index, and bleeding pattern.
From July to November 2018, we enrolled 32 individuals; 20 completed the study (14 continuing testosterone users, 6 new users). Median age was 23 years (range 18−37 years). Bleeding or spotting during the study period was noted by 41% of participants (13/32). Among continuing users, median testosterone therapy duration was 11 months (range 1−60 months). A single ovulation was observed out of a total of 61 combined months of testosterone use; however, several transient rises in pregnanediol-3-glucoronide followed by bleeding episodes were suggestive of 7 dysfunctional ovulatory cycles among 7 individuals. There was no difference in antimüllerian hormone from baseline to 12 weeks between participants initiating testosterone and continuing users of testosterone. We did not have the power to examine our intended predictors given the low numbers of ovulatory events, but found that longer time on testosterone and presence of vaginal bleeding over 12 weeks were associated with transient rises in pregnanediol-3-glucoronide.
This study suggests that testosterone rapidly induces hypothalamic−pituitary−gonadal suppression, resulting in anovulation in a proportion of new users. Importantly, these data also suggest that some long-term testosterone users break through the hormonal suppression and experience an ovulatory event, thereby raising concerns pertaining to the need for contraception in transmasculine individuals engaged in sexual intercourse with sperm-producing partners. Given the small number of overall participants, this work is hypothesis generating. Larger studies are needed to confirm and to clarify these findings. |
|---|---|
| AbstractList | An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have directly examined ovulatory function in transmasculine individuals using injectable testosterone.BACKGROUNDAn estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have directly examined ovulatory function in transmasculine individuals using injectable testosterone.Our primary objective was to determine the effect of testosterone on ovulatory suppression in transmasculine individuals. Secondary objectives were to determine predictors of ovulation in transmasculine individuals on testosterone, and to assess the effect of testosterone on antimüllerian hormone.OBJECTIVESOur primary objective was to determine the effect of testosterone on ovulatory suppression in transmasculine individuals. Secondary objectives were to determine predictors of ovulation in transmasculine individuals on testosterone, and to assess the effect of testosterone on antimüllerian hormone.This prospective observational study recruited participants from a community clinic that provides gender-affirming hormone therapy. Enrolled individuals were assigned female at birth and were currently using or seeking to initiate masculinizing therapy with injectable testosterone esters (transmasculine individuals). Over a 12-week study period, participants collected daily urine samples for pregnanediol-3-glucoronide testing and completed daily electronic bleeding diaries. We assessed monthly serum mid-dosing interval testosterone, estradiol and sex hormone binding globulin, and antimüllerian hormone values at baseline and study end. Ovulation was defined as pregnanediol-3-glucoronide greater than 5 μg/mL for 3 consecutive days. The primary outcome was the proportion of participants who ovulated during the study period. We examined predictors of ovulation such as age, length of time on testosterone, serum testosterone levels, body mass index, and bleeding pattern.MATERIALS AND METHODSThis prospective observational study recruited participants from a community clinic that provides gender-affirming hormone therapy. Enrolled individuals were assigned female at birth and were currently using or seeking to initiate masculinizing therapy with injectable testosterone esters (transmasculine individuals). Over a 12-week study period, participants collected daily urine samples for pregnanediol-3-glucoronide testing and completed daily electronic bleeding diaries. We assessed monthly serum mid-dosing interval testosterone, estradiol and sex hormone binding globulin, and antimüllerian hormone values at baseline and study end. Ovulation was defined as pregnanediol-3-glucoronide greater than 5 μg/mL for 3 consecutive days. The primary outcome was the proportion of participants who ovulated during the study period. We examined predictors of ovulation such as age, length of time on testosterone, serum testosterone levels, body mass index, and bleeding pattern.From July to November 2018, we enrolled 32 individuals; 20 completed the study (14 continuing testosterone users, 6 new users). Median age was 23 years (range 18-37 years). Bleeding or spotting during the study period was noted by 41% of participants (13/32). Among continuing users, median testosterone therapy duration was 11 months (range 1-60 months). A single ovulation was observed out of a total of 61 combined months of testosterone use; however, several transient rises in pregnanediol-3-glucoronide followed by bleeding episodes were suggestive of 7 dysfunctional ovulatory cycles among 7 individuals. There was no difference in antimüllerian hormone from baseline to 12 weeks between participants initiating testosterone and continuing users of testosterone. We did not have the power to examine our intended predictors given the low numbers of ovulatory events, but found that longer time on testosterone and presence of vaginal bleeding over 12 weeks were associated with transient rises in pregnanediol-3-glucoronide.RESULTSFrom July to November 2018, we enrolled 32 individuals; 20 completed the study (14 continuing testosterone users, 6 new users). Median age was 23 years (range 18-37 years). Bleeding or spotting during the study period was noted by 41% of participants (13/32). Among continuing users, median testosterone therapy duration was 11 months (range 1-60 months). A single ovulation was observed out of a total of 61 combined months of testosterone use; however, several transient rises in pregnanediol-3-glucoronide followed by bleeding episodes were suggestive of 7 dysfunctional ovulatory cycles among 7 individuals. There was no difference in antimüllerian hormone from baseline to 12 weeks between participants initiating testosterone and continuing users of testosterone. We did not have the power to examine our intended predictors given the low numbers of ovulatory events, but found that longer time on testosterone and presence of vaginal bleeding over 12 weeks were associated with transient rises in pregnanediol-3-glucoronide.This study suggests that testosterone rapidly induces hypothalamic-pituitary-gonadal suppression, resulting in anovulation in a proportion of new users. Importantly, these data also suggest that some long-term testosterone users break through the hormonal suppression and experience an ovulatory event, thereby raising concerns pertaining to the need for contraception in transmasculine individuals engaged in sexual intercourse with sperm-producing partners. Given the small number of overall participants, this work is hypothesis generating. Larger studies are needed to confirm and to clarify these findings.CONCLUSIONThis study suggests that testosterone rapidly induces hypothalamic-pituitary-gonadal suppression, resulting in anovulation in a proportion of new users. Importantly, these data also suggest that some long-term testosterone users break through the hormonal suppression and experience an ovulatory event, thereby raising concerns pertaining to the need for contraception in transmasculine individuals engaged in sexual intercourse with sperm-producing partners. Given the small number of overall participants, this work is hypothesis generating. Larger studies are needed to confirm and to clarify these findings. An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have directly examined ovulatory function in transmasculine individuals using injectable testosterone. Our primary objective was to determine the effect of testosterone on ovulatory suppression in transmasculine individuals. Secondary objectives were to determine predictors of ovulation in transmasculine individuals on testosterone, and to assess the effect of testosterone on antimüllerian hormone. This prospective observational study recruited participants from a community clinic that provides gender-affirming hormone therapy. Enrolled individuals were assigned female at birth and were currently using or seeking to initiate masculinizing therapy with injectable testosterone esters (transmasculine individuals). Over a 12-week study period, participants collected daily urine samples for pregnanediol-3-glucoronide testing and completed daily electronic bleeding diaries. We assessed monthly serum mid-dosing interval testosterone, estradiol and sex hormone binding globulin, and antimüllerian hormone values at baseline and study end. Ovulation was defined as pregnanediol-3-glucoronide greater than 5 μg/mL for 3 consecutive days. The primary outcome was the proportion of participants who ovulated during the study period. We examined predictors of ovulation such as age, length of time on testosterone, serum testosterone levels, body mass index, and bleeding pattern. From July to November 2018, we enrolled 32 individuals; 20 completed the study (14 continuing testosterone users, 6 new users). Median age was 23 years (range 18-37 years). Bleeding or spotting during the study period was noted by 41% of participants (13/32). Among continuing users, median testosterone therapy duration was 11 months (range 1-60 months). A single ovulation was observed out of a total of 61 combined months of testosterone use; however, several transient rises in pregnanediol-3-glucoronide followed by bleeding episodes were suggestive of 7 dysfunctional ovulatory cycles among 7 individuals. There was no difference in antimüllerian hormone from baseline to 12 weeks between participants initiating testosterone and continuing users of testosterone. We did not have the power to examine our intended predictors given the low numbers of ovulatory events, but found that longer time on testosterone and presence of vaginal bleeding over 12 weeks were associated with transient rises in pregnanediol-3-glucoronide. This study suggests that testosterone rapidly induces hypothalamic-pituitary-gonadal suppression, resulting in anovulation in a proportion of new users. Importantly, these data also suggest that some long-term testosterone users break through the hormonal suppression and experience an ovulatory event, thereby raising concerns pertaining to the need for contraception in transmasculine individuals engaged in sexual intercourse with sperm-producing partners. Given the small number of overall participants, this work is hypothesis generating. Larger studies are needed to confirm and to clarify these findings. An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone. No studies have directly examined ovulatory function in transmasculine individuals using injectable testosterone. Our primary objective was to determine the effect of testosterone on ovulatory suppression in transmasculine individuals. Secondary objectives were to determine predictors of ovulation in transmasculine individuals on testosterone, and to assess the effect of testosterone on antimüllerian hormone. This prospective observational study recruited participants from a community clinic that provides gender-affirming hormone therapy. Enrolled individuals were assigned female at birth and were currently using or seeking to initiate masculinizing therapy with injectable testosterone esters (transmasculine individuals). Over a 12-week study period, participants collected daily urine samples for pregnanediol-3-glucoronide testing and completed daily electronic bleeding diaries. We assessed monthly serum mid-dosing interval testosterone, estradiol and sex hormone binding globulin, and antimüllerian hormone values at baseline and study end. Ovulation was defined as pregnanediol-3-glucoronide greater than 5 μg/mL for 3 consecutive days. The primary outcome was the proportion of participants who ovulated during the study period. We examined predictors of ovulation such as age, length of time on testosterone, serum testosterone levels, body mass index, and bleeding pattern. From July to November 2018, we enrolled 32 individuals; 20 completed the study (14 continuing testosterone users, 6 new users). Median age was 23 years (range 18−37 years). Bleeding or spotting during the study period was noted by 41% of participants (13/32). Among continuing users, median testosterone therapy duration was 11 months (range 1−60 months). A single ovulation was observed out of a total of 61 combined months of testosterone use; however, several transient rises in pregnanediol-3-glucoronide followed by bleeding episodes were suggestive of 7 dysfunctional ovulatory cycles among 7 individuals. There was no difference in antimüllerian hormone from baseline to 12 weeks between participants initiating testosterone and continuing users of testosterone. We did not have the power to examine our intended predictors given the low numbers of ovulatory events, but found that longer time on testosterone and presence of vaginal bleeding over 12 weeks were associated with transient rises in pregnanediol-3-glucoronide. This study suggests that testosterone rapidly induces hypothalamic−pituitary−gonadal suppression, resulting in anovulation in a proportion of new users. Importantly, these data also suggest that some long-term testosterone users break through the hormonal suppression and experience an ovulatory event, thereby raising concerns pertaining to the need for contraception in transmasculine individuals engaged in sexual intercourse with sperm-producing partners. Given the small number of overall participants, this work is hypothesis generating. Larger studies are needed to confirm and to clarify these findings. |
| Author | Magaret, Amalia S. Neal-Perry, Genevieve Ellis, Simon Adriane Prager, Sarah W. Taub, Rebecca L. Micks, Elizabeth A. |
| Author_xml | – sequence: 1 givenname: Rebecca L. orcidid: 0000-0003-1641-7575 surname: Taub fullname: Taub, Rebecca L. email: TaubRL@sutterhealth.org organization: Department of Obstetrics and Gynecology, University of Washington, Seattle, WA – sequence: 2 givenname: Simon Adriane surname: Ellis fullname: Ellis, Simon Adriane organization: The Permanente Medical Group; Seattle, WA – sequence: 3 givenname: Genevieve surname: Neal-Perry fullname: Neal-Perry, Genevieve organization: Department of Obstetrics and Gynecology, University of Washington, Seattle, WA – sequence: 4 givenname: Amalia S. surname: Magaret fullname: Magaret, Amalia S. organization: Department of Biostatistics, University of Washington, Seattle, WA – sequence: 5 givenname: Sarah W. surname: Prager fullname: Prager, Sarah W. organization: Department of Obstetrics and Gynecology, University of Washington, Seattle, WA – sequence: 6 givenname: Elizabeth A. surname: Micks fullname: Micks, Elizabeth A. organization: Department of Obstetrics and Gynecology, University of Washington, Seattle, WA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32044312$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9v1DAQxS1URLeFL8AB5cglYWxvvA5CSKjin1TBpZwtxx63XrJ2sZ2V9tvjaEsFPZTTyPb7zRvPOyMnIQYk5CWFjgIVb7ad3sbrjgGDDmgH_fCErCgMm1ZIIU_ICgBYO_CNPCVnOW-XIxvYM3LKGazXnLIV-XZ1gw06h6Y00TUFc4m5YKpOTQxN3M-TLjEdGjcHU3y98qEpSYe809nMk686H6zfezvrKT8nT10t-OKunpMfnz5eXXxpL79__nrx4bI1PYjSDrJ33EppRyfE4BigMNwNQjArHeMjd5IxDuCA2RHcQHHNrR6R9o4JrOw5eX_sezuPO7QGQ51pUrfJ73Q6qKi9-vcl-Bt1HfdKMi6h57XB67sGKf6a66_VzmeD06QDxjkrxnveSy43Q5W--tvr3uTPEquAHQUmxZwTunsJBbUkpbZqSUotSSmgqiZVIfkAMr7oZcN1Xj89jr47olg3vPeYVDYeg0HrU81R2egfx98-wE2N0Rs9_cTD_-DfX7TEdA |
| CitedBy_id | crossref_primary_10_1080_26895269_2024_2392685 crossref_primary_10_1016_j_fertnstert_2022_04_012 crossref_primary_10_1210_endocr_bqae113 crossref_primary_10_1097_og9_0000000000000003 crossref_primary_10_1097_AOG_0000000000005527 crossref_primary_10_1016_j_srhc_2022_100733 crossref_primary_10_1007_s10304_024_00583_0 crossref_primary_10_1016_j_contraception_2020_04_001 crossref_primary_10_1097_GCO_0000000000000729 crossref_primary_10_1111_andr_13703 crossref_primary_10_1097_AOG_0000000000005440 crossref_primary_10_1177_26334941231158251 crossref_primary_10_1089_trgh_2022_0023 crossref_primary_10_1007_s40618_023_02296_w crossref_primary_10_1016_j_bpobgyn_2023_102312 crossref_primary_10_1093_ofid_ofac091 crossref_primary_10_1002_bsl_2684 crossref_primary_10_1016_j_contraception_2024_110784 crossref_primary_10_1016_j_xfnr_2025_100093 crossref_primary_10_1016_j_jpag_2022_10_007 crossref_primary_10_1016_j_anireprosci_2022_107047 crossref_primary_10_1016_j_ogc_2023_10_001 crossref_primary_10_1016_j_ajog_2023_12_036 crossref_primary_10_1016_j_beem_2024_101908 crossref_primary_10_1080_26895269_2023_2284775 crossref_primary_10_2147_OAJC_S368621 crossref_primary_10_4103_aja202262 crossref_primary_10_1007_s13669_020_00298_6 crossref_primary_10_5858_arpa_2021_0199_OA crossref_primary_10_1210_clinem_dgaa529 crossref_primary_10_1093_jalm_jfaa169 crossref_primary_10_1007_s13669_024_00384_z crossref_primary_10_1093_jsxmed_qdad135 crossref_primary_10_1097_GRF_0000000000000646 crossref_primary_10_1007_s11930_023_00355_0 crossref_primary_10_1155_2022_6246867 crossref_primary_10_1016_j_jpag_2020_06_001 crossref_primary_10_15585_mmwr_rr7303a1 crossref_primary_10_1016_j_gofs_2022_11_008 crossref_primary_10_1186_s12967_021_03103_x crossref_primary_10_1016_j_beem_2022_101617 crossref_primary_10_1093_humrep_deab169 crossref_primary_10_1080_02646838_2025_2540588 crossref_primary_10_3389_fendo_2022_970439 crossref_primary_10_1111_jmwh_13397 crossref_primary_10_1111_jmwh_13310 crossref_primary_10_1080_27703371_2025_2545818 crossref_primary_10_3389_fendo_2022_936765 crossref_primary_10_1097_OGX_0000000000001411 crossref_primary_10_1089_trgh_2020_0047 crossref_primary_10_1016_j_jpag_2024_07_007 crossref_primary_10_1097_GRF_0000000000000710 crossref_primary_10_1080_13625187_2021_2000960 crossref_primary_10_1016_j_bpobgyn_2025_102652 crossref_primary_10_1016_j_cppeds_2022_101239 crossref_primary_10_1016_j_jcte_2024_100353 crossref_primary_10_1016_j_jmig_2024_05_026 crossref_primary_10_1080_26895269_2022_2100644 crossref_primary_10_1016_j_jaad_2021_03_113 crossref_primary_10_1016_j_jpag_2021_04_004 crossref_primary_10_1016_j_japh_2023_08_016 crossref_primary_10_1016_j_ajog_2024_06_004 crossref_primary_10_1016_j_jpag_2022_09_002 crossref_primary_10_1093_humrep_dead158 crossref_primary_10_1007_s10508_023_02787_0 crossref_primary_10_1007_s13669_020_00297_7 crossref_primary_10_1038_s41585_020_0372_2 |
| Cites_doi | 10.1210/jc.2016-4017 10.1016/j.contraception.2019.07.146 10.1016/j.jbi.2008.08.010 10.1093/clinchem/37.6.838 10.21037/tau.2016.09.04 10.1152/ajpendo.00381.2002 10.1016/0010-7824(86)90006-5 10.1373/49.7.1139 10.1016/j.jana.2009.06.001 10.1097/AOG.0000000000000540 10.1016/j.fertnstert.2008.08.025 10.1007/s11136-006-0002-3 10.1080/13691058.2016.1216605 10.1210/jc.2007-2165 10.1016/j.maturitas.2017.10.012 10.4158/EP-2017-0203 10.1016/j.contraception.2016.09.005 10.1016/j.contraception.2018.06.006 10.1016/j.cca.2007.07.013 10.1016/0010-7824(86)90095-8 10.1089/apc.2010.0059 10.1016/j.steroids.2013.06.006 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Inc. Copyright © 2020 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2020 Elsevier Inc. – notice: Copyright © 2020 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1016/j.ajog.2020.01.059 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6868 |
| EndPage | 229.e8 |
| ExternalDocumentID | PMC8238053 32044312 10_1016_j_ajog_2020_01_059 S0002937820301344 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Society of Family Planning funderid: https://doi.org/10.13039/100012297 |
| GroupedDBID | --- --K --M -ET .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 2KS 354 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6J9 7-5 85S 8F7 8P~ AAEDT AAEDW AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYJJ AAYWO ABBQC ABCQX ABDPE ABFNM ABFRF ABJNI ABMAC ABMZM ABOCM ABPMR ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFCHL AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGNAY AGQPQ AGUBO AGYEJ AHDLI AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 C5W CAG COF CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IH2 IHE J1W K-O KOM LPU M41 MO0 N4W N9A NEJ NQ- O-L O9- OAUVE OBH OCB OGEVE OHH OHT OMK OQ. OVD P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ RXW SDF SEL SES SEW SJN SPCBC SSH SSZ T5K TAE TEORI TWZ UDS UGJ UHB UHS UHU UKR UNMZH UV1 VH1 VVN WH7 WOQ WOW X6Y X7M XFW YFH YOC YYQ YZZ Z5R ZGI ZXP ZY1 ~G- ~H1 ~HD 0SF AACTN AAIAV ADMBK ADOJD AFCTW AFDAS AFKWA AJOXV AMFUW G8K NCXOZ RIG ZA5 AAYXX CITATION XRW NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c506t-985f3d88dbf669f20e6c3f9662d8f23b3f822300f02db0f91e43dabe15f26e5f3 |
| ISICitedReferencesCount | 80 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000556986200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0002-9378 1097-6868 |
| IngestDate | Tue Sep 30 16:46:56 EDT 2025 Thu Oct 02 07:49:04 EDT 2025 Wed Feb 19 02:30:03 EST 2025 Tue Nov 18 21:02:24 EST 2025 Sat Nov 29 07:32:22 EST 2025 Thu Jun 13 14:31:01 EDT 2024 Tue Oct 14 19:36:05 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | sexual and reproductive health contraception gender affirmation transgender fertility |
| Language | English |
| License | Copyright © 2020 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c506t-985f3d88dbf669f20e6c3f9662d8f23b3f822300f02db0f91e43dabe15f26e5f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-1641-7575 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8238053 |
| PMID | 32044312 |
| PQID | 2353583879 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8238053 proquest_miscellaneous_2353583879 pubmed_primary_32044312 crossref_primary_10_1016_j_ajog_2020_01_059 crossref_citationtrail_10_1016_j_ajog_2020_01_059 elsevier_sciencedirect_doi_10_1016_j_ajog_2020_01_059 elsevier_clinicalkey_doi_10_1016_j_ajog_2020_01_059 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-01 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of obstetrics and gynecology |
| PublicationTitleAlternate | Am J Obstet Gynecol |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Cekan, Beksac, Wang (bib17) 1986; 33 Munro, Stabenfeldt, Cragun, Addiego, Overstreet, Lasley (bib19) 1991; 37 Unger (bib7) 2016; 5 Santoro, Brown, Adel, Skurnick (bib18) 1996; 81 Santoro, Crawford, Lasley (bib27) 2008; 93 Stark, Hughto, Charlton, Deutsch, Potter, Reisner (bib15) 2019; 100 Xavier, Bradford (bib14) Belsey, Machin, d’Arcangues (bib24) 1986; 34 bib30 Accessed July 18, 2017. Sevelius (bib12) 2009; 20 Santoro, Crawford, Allsworth (bib22) 2003; 284 Light, Obedin-Maliver, Sevelius, Kerns (bib29) 2014; 124 Colizzi, Costa, Pace, Todarello (bib4) 2013; 10 O’Connor, Brindle, Holman (bib20) 2003; 49 Vita, Settineri, Liotta, Benvenga, Trimarchi (bib31) 2018; 107 Santoro, Crawford, El Khoudary (bib26) March 2017; 102 bib23 Harris, Taylor, Thielke, Payne, Gonzalez, Conde (bib25) 2009; 42 Rochester, Jain, Polotsky (bib28) 2009; 92 Ecochard, Leiva, Bouchard (bib21) 2013; 78 Deutsch MB, Ed. Transgender-PGACG-6-17-16. Available at: pdf. Cipres, Seidman, Cloniger, Nova, O’Shea, Obedin-Maliver (bib13) 2017; 95 Rachlin, Green, Lombardi (bib9) 2008; 54 Dadasovich, Auerswald, Minnis, Raymond, McFarland, Wilson (bib11) 2017; 19 Moal, Mathieu, Reynier, Malthièry, Gallois (bib33) 2007; 386 Flores, Herman, Gates, Brown (bib6) bib1 bib2 Light, Wang, Zeymo, Gomez-Lobo (bib16) 2018; 98 Flores, Herman, Gates, Brown (bib8) Newfield, Hart, Dibble, Kohler (bib5) 2006; 15 Chan, Jolly, Liang, Weinand, Safer (bib32) 2018; 24 Reisner, Perkovich, Mimiaga (bib10) 2010; 24 Chan (10.1016/j.ajog.2020.01.059_bib32) 2018; 24 Reisner (10.1016/j.ajog.2020.01.059_bib10) 2010; 24 10.1016/j.ajog.2020.01.059_bib3 Xavier (10.1016/j.ajog.2020.01.059_bib14) Munro (10.1016/j.ajog.2020.01.059_bib19) 1991; 37 Light (10.1016/j.ajog.2020.01.059_bib16) 2018; 98 Santoro (10.1016/j.ajog.2020.01.059_bib18) 1996; 81 Moal (10.1016/j.ajog.2020.01.059_bib33) 2007; 386 Flores (10.1016/j.ajog.2020.01.059_bib8) Flores (10.1016/j.ajog.2020.01.059_bib6) Vita (10.1016/j.ajog.2020.01.059_bib31) 2018; 107 Stark (10.1016/j.ajog.2020.01.059_bib15) 2019; 100 Cipres (10.1016/j.ajog.2020.01.059_bib13) 2017; 95 Sevelius (10.1016/j.ajog.2020.01.059_bib12) 2009; 20 Belsey (10.1016/j.ajog.2020.01.059_bib24) 1986; 34 Unger (10.1016/j.ajog.2020.01.059_bib7) 2016; 5 O’Connor (10.1016/j.ajog.2020.01.059_bib20) 2003; 49 Harris (10.1016/j.ajog.2020.01.059_bib25) 2009; 42 Santoro (10.1016/j.ajog.2020.01.059_bib26) 2017; 102 Santoro (10.1016/j.ajog.2020.01.059_bib22) 2003; 284 Dadasovich (10.1016/j.ajog.2020.01.059_bib11) 2017; 19 Santoro (10.1016/j.ajog.2020.01.059_bib27) 2008; 93 Rachlin (10.1016/j.ajog.2020.01.059_bib9) 2008; 54 Cekan (10.1016/j.ajog.2020.01.059_bib17) 1986; 33 Newfield (10.1016/j.ajog.2020.01.059_bib5) 2006; 15 Rochester (10.1016/j.ajog.2020.01.059_bib28) 2009; 92 Light (10.1016/j.ajog.2020.01.059_bib29) 2014; 124 Ecochard (10.1016/j.ajog.2020.01.059_bib21) 2013; 78 Colizzi (10.1016/j.ajog.2020.01.059_bib4) 2013; 10 |
| References_xml | – volume: 34 start-page: 253 year: 1986 end-page: 260 ident: bib24 article-title: The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction publication-title: Contraception – volume: 284 start-page: E521 year: 2003 end-page: E530 ident: bib22 article-title: Assessing menstrual cycles with urinary hormone assays publication-title: Am J Physiol Endocrinol Metab – volume: 78 start-page: 1035 year: 2013 end-page: 1040 ident: bib21 article-title: Use of urinary pregnanediol 3-glucuronide to confirm ovulation publication-title: Steroids – volume: 19 start-page: 256 year: 2017 end-page: 266 ident: bib11 article-title: Testosterone and sexual risk among transmen: a mixed methods exploratory study publication-title: Cult Health Sex – volume: 107 start-page: 92 year: 2018 end-page: 96 ident: bib31 article-title: Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study publication-title: Maturitas – volume: 102 start-page: 2218 year: March 2017 end-page: 2229 ident: bib26 article-title: Menstrual cycle hormone changes in women traversing the menopause: study of women’s health across the nation publication-title: J Clin Endocrinol Metab – ident: bib8 article-title: USTS-Full-Report-Dec17.pdf – volume: 20 start-page: 398 year: 2009 end-page: 410 ident: bib12 article-title: There’s no pamphlet for the kind of sex I have: HIV-related risk factors and protective behaviors among transgender men who have sex with non-transgender men publication-title: J Assoc Nurses AIDS Care – volume: 33 start-page: 327 year: 1986 end-page: 345 ident: bib17 article-title: The prediction and/or detection of ovulation by means of urinary steroid assays publication-title: Contraception – volume: 10 start-page: 3049 year: 2013 end-page: 3058 ident: bib4 article-title: Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style publication-title: J Sex Med – reference: Deutsch MB, Ed. Transgender-PGACG-6-17-16. Available at: pdf. – volume: 15 start-page: 1447 year: 2006 end-page: 1457 ident: bib5 article-title: Female-to-male transgender quality of life publication-title: Qual Life Res – volume: 24 start-page: 501 year: 2010 end-page: 513 ident: bib10 article-title: A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men publication-title: AIDS Patient Care STDS – volume: 81 start-page: 1495 year: 1996 end-page: 1501 ident: bib18 article-title: Characterization of reproductive hormonal dynamics in the perimenopause publication-title: J Clin Endocrinol Metab – ident: bib2 article-title: World Professional Association for Transgender Health. Standards of Care V7 - 2011 WPATH (2)(1).pdf – ident: bib23 article-title: Cedar River Clinics. MasculinizationProtocol.pdf – volume: 42 start-page: 377 year: 2009 end-page: 381 ident: bib25 article-title: Research Electronic Data Capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support publication-title: J Biomed Inform – ident: bib1 article-title: American Psychiatric Association. What is gender dysphoria? – volume: 49 start-page: 1139 year: 2003 end-page: 1148 ident: bib20 article-title: Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research publication-title: Clin Chem – volume: 98 start-page: 266 year: 2018 end-page: 269 ident: bib16 article-title: Family planning and contraception use in transgender men publication-title: Contraception – volume: 54 start-page: 243 year: 2008 end-page: 258 ident: bib9 article-title: Utilization of health care among female-to-male transgender individuals in the United States publication-title: J Homosex – volume: 92 start-page: 1410 year: 2009 end-page: 1415 ident: bib28 article-title: Partial recovery of luteal function after bariatric surgery in obese women publication-title: Fertil Steril – volume: 5 start-page: 877 year: 2016 end-page: 884 ident: bib7 article-title: Hormone therapy for transgender patients publication-title: Transl Androl Urol – ident: bib6 article-title: How-Many-Adults-Identify-as-Transgender-in-the-United-States.pdf – volume: 100 start-page: 468 year: 2019 end-page: 473 ident: bib15 article-title: The contraceptive and reproductive history and planning goals of trans-masculine adults: a mixed-methods study publication-title: Contraception – volume: 37 start-page: 838 year: 1991 end-page: 844 ident: bib19 article-title: Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay publication-title: Clin Chem – volume: 95 start-page: 186 year: 2017 end-page: 189 ident: bib13 article-title: Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco publication-title: Contraception – volume: 124 start-page: 1120 year: 2014 end-page: 1127 ident: bib29 article-title: Transgender men who experienced pregnancy after female-to-male gender transitioning publication-title: Obstet Gynecol – volume: 386 start-page: 12 year: 2007 end-page: 19 ident: bib33 article-title: Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques publication-title: Clin Chim Acta – reference: . Accessed July 18, 2017. – ident: bib30 article-title: Pfizer. DEPO®-TESTOSTERONE (testosterone cipionate) Description | Pfizer Medical Information–US – ident: bib14 article-title: THIFocusGroupReport.pdf – volume: 24 start-page: 329 year: 2018 end-page: 333 ident: bib32 article-title: Estrogen levels do not rise with testosterone treatment for transgender men publication-title: Endocr Pract – volume: 93 start-page: 1711 year: 2008 end-page: 1721 ident: bib27 article-title: Factors related to declining luteal function in women during the menopausal transition publication-title: J Clin Endocrinol Metab – volume: 102 start-page: 2218 year: 2017 ident: 10.1016/j.ajog.2020.01.059_bib26 article-title: Menstrual cycle hormone changes in women traversing the menopause: study of women’s health across the nation publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-4017 – volume: 100 start-page: 468 year: 2019 ident: 10.1016/j.ajog.2020.01.059_bib15 article-title: The contraceptive and reproductive history and planning goals of trans-masculine adults: a mixed-methods study publication-title: Contraception doi: 10.1016/j.contraception.2019.07.146 – ident: 10.1016/j.ajog.2020.01.059_bib14 – volume: 42 start-page: 377 year: 2009 ident: 10.1016/j.ajog.2020.01.059_bib25 article-title: Research Electronic Data Capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support publication-title: J Biomed Inform doi: 10.1016/j.jbi.2008.08.010 – ident: 10.1016/j.ajog.2020.01.059_bib8 – volume: 37 start-page: 838 year: 1991 ident: 10.1016/j.ajog.2020.01.059_bib19 article-title: Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay publication-title: Clin Chem doi: 10.1093/clinchem/37.6.838 – volume: 54 start-page: 243 year: 2008 ident: 10.1016/j.ajog.2020.01.059_bib9 article-title: Utilization of health care among female-to-male transgender individuals in the United States publication-title: J Homosex – volume: 5 start-page: 877 year: 2016 ident: 10.1016/j.ajog.2020.01.059_bib7 article-title: Hormone therapy for transgender patients publication-title: Transl Androl Urol doi: 10.21037/tau.2016.09.04 – volume: 284 start-page: E521 year: 2003 ident: 10.1016/j.ajog.2020.01.059_bib22 article-title: Assessing menstrual cycles with urinary hormone assays publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00381.2002 – volume: 34 start-page: 253 year: 1986 ident: 10.1016/j.ajog.2020.01.059_bib24 article-title: The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction publication-title: Contraception doi: 10.1016/0010-7824(86)90006-5 – volume: 49 start-page: 1139 year: 2003 ident: 10.1016/j.ajog.2020.01.059_bib20 article-title: Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research publication-title: Clin Chem doi: 10.1373/49.7.1139 – volume: 20 start-page: 398 year: 2009 ident: 10.1016/j.ajog.2020.01.059_bib12 article-title: There’s no pamphlet for the kind of sex I have: HIV-related risk factors and protective behaviors among transgender men who have sex with non-transgender men publication-title: J Assoc Nurses AIDS Care doi: 10.1016/j.jana.2009.06.001 – volume: 124 start-page: 1120 year: 2014 ident: 10.1016/j.ajog.2020.01.059_bib29 article-title: Transgender men who experienced pregnancy after female-to-male gender transitioning publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000000540 – volume: 92 start-page: 1410 year: 2009 ident: 10.1016/j.ajog.2020.01.059_bib28 article-title: Partial recovery of luteal function after bariatric surgery in obese women publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2008.08.025 – volume: 15 start-page: 1447 year: 2006 ident: 10.1016/j.ajog.2020.01.059_bib5 article-title: Female-to-male transgender quality of life publication-title: Qual Life Res doi: 10.1007/s11136-006-0002-3 – volume: 19 start-page: 256 year: 2017 ident: 10.1016/j.ajog.2020.01.059_bib11 article-title: Testosterone and sexual risk among transmen: a mixed methods exploratory study publication-title: Cult Health Sex doi: 10.1080/13691058.2016.1216605 – volume: 93 start-page: 1711 year: 2008 ident: 10.1016/j.ajog.2020.01.059_bib27 article-title: Factors related to declining luteal function in women during the menopausal transition publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-2165 – volume: 107 start-page: 92 year: 2018 ident: 10.1016/j.ajog.2020.01.059_bib31 article-title: Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study publication-title: Maturitas doi: 10.1016/j.maturitas.2017.10.012 – volume: 24 start-page: 329 year: 2018 ident: 10.1016/j.ajog.2020.01.059_bib32 article-title: Estrogen levels do not rise with testosterone treatment for transgender men publication-title: Endocr Pract doi: 10.4158/EP-2017-0203 – volume: 95 start-page: 186 year: 2017 ident: 10.1016/j.ajog.2020.01.059_bib13 article-title: Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco publication-title: Contraception doi: 10.1016/j.contraception.2016.09.005 – volume: 98 start-page: 266 year: 2018 ident: 10.1016/j.ajog.2020.01.059_bib16 article-title: Family planning and contraception use in transgender men publication-title: Contraception doi: 10.1016/j.contraception.2018.06.006 – ident: 10.1016/j.ajog.2020.01.059_bib3 – volume: 386 start-page: 12 year: 2007 ident: 10.1016/j.ajog.2020.01.059_bib33 article-title: Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques publication-title: Clin Chim Acta doi: 10.1016/j.cca.2007.07.013 – volume: 81 start-page: 1495 year: 1996 ident: 10.1016/j.ajog.2020.01.059_bib18 article-title: Characterization of reproductive hormonal dynamics in the perimenopause publication-title: J Clin Endocrinol Metab – volume: 33 start-page: 327 year: 1986 ident: 10.1016/j.ajog.2020.01.059_bib17 article-title: The prediction and/or detection of ovulation by means of urinary steroid assays publication-title: Contraception doi: 10.1016/0010-7824(86)90095-8 – ident: 10.1016/j.ajog.2020.01.059_bib6 – volume: 24 start-page: 501 year: 2010 ident: 10.1016/j.ajog.2020.01.059_bib10 article-title: A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men publication-title: AIDS Patient Care STDS doi: 10.1089/apc.2010.0059 – volume: 78 start-page: 1035 year: 2013 ident: 10.1016/j.ajog.2020.01.059_bib21 article-title: Use of urinary pregnanediol 3-glucuronide to confirm ovulation publication-title: Steroids doi: 10.1016/j.steroids.2013.06.006 – volume: 10 start-page: 3049 year: 2013 ident: 10.1016/j.ajog.2020.01.059_bib4 article-title: Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style publication-title: J Sex Med |
| SSID | ssj0002292 |
| Score | 2.5783627 |
| Snippet | An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 229.e1 |
| SubjectTerms | contraception fertility gender affirmation sexual and reproductive health |
| Title | The effect of testosterone on ovulatory function in transmasculine individuals |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0002937820301344 https://dx.doi.org/10.1016/j.ajog.2020.01.059 https://www.ncbi.nlm.nih.gov/pubmed/32044312 https://www.proquest.com/docview/2353583879 https://pubmed.ncbi.nlm.nih.gov/PMC8238053 |
| Volume | 223 |
| WOSCitedRecordID | wos000556986200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1097-6868 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002292 issn: 0002-9378 databaseCode: AIEXJ dateStart: 20160801 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfGZTISb1Wi1G4S57FCQ4BGNWlF6puViz1abcnUm8a_4idyHF_qFDbYAy9Rm8Su6_PZ5xz7nM8IvY9yQEalw8rjYJixBMYcKYIBzWWbKlloEteTdDxm02l22uv9tLkwm4u0rtn1dXb1X0UN90DYKnX2DuJ2lcIN-AxChyuIHa7_LHgdpdHu_6uTYxQZQgPWpLINN-q8LrWxrjSai3RUGuuyDUqdtTQiNktr6RuvbnfHo5toCqhcsfxrrufzH7UoOyv1k3xdeHLsn4R-uEiLojPAS90fVdA5203-MViwwalY6G1-xY4NGnzjReq25_O2U9ulWqvpn4X-CgbZxs_5szKYScyflYlOQzbwI_4ca5ZIhP0WCvZHZaDXJeZhPm_OQ_XDLUGrISDvMG_vaEQXp2hD4OZc1cFVHTwacKhjDx2QNM5gHj0YfT6efnHaH9pDrMul_pNJ1NIxhbstuckY-t3Z2Y3Z9YygySP00HgveKRR9xj1RP0E3f9q4jOeojGAD2vw4UZiH3y4qbEDH7bgw7Mad8GHPfA9Q98-Hk8-fArMiR1BGUfJKshYLGnFWFXIJMkkiURSUgkeNamYJLSgEuxRGkUyIlURyWwghrTKCzGIJUkElH2O9mto0kuE4ZEAX0EOEwY-fw6eQEUElYKq8xbKghyige06Xho6e3WqygW_WWiHqO_KXGkyl1vfplYi3KYpg2LlAK9bS8WulDFitXH613LvrNA5zPBq2w7GXLNeckJjqoIbUnjnhQaBaz0l0RBcAOiNtAMP94Jij-8-qWffWxZ5BsY6aOBXd-qT1-jBdgS_QfurxVq8RffKzWq2XByhvXTKjsyI-AV0f-mY |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+testosterone+on+ovulatory+function+in+transmasculine+individuals&rft.jtitle=American+journal+of+obstetrics+and+gynecology&rft.au=Taub%2C+Rebecca+L.&rft.au=Ellis%2C+Simon+Adriane&rft.au=Neal-Perry%2C+Genevieve&rft.au=Magaret%2C+Amalia+S.&rft.date=2020-08-01&rft.issn=0002-9378&rft.volume=223&rft.issue=2&rft.spage=229&rft.epage=229.e8&rft_id=info:doi/10.1016%2Fj.ajog.2020.01.059&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ajog_2020_01_059 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9378&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9378&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9378&client=summon |